© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to January
oral WT and F877L mut. AR inhibitor
completed Ph. I/II trial in mCPRC
no hepatotox. vs. bioactivated prior lead
J. Med. Chem., Jan. 20, 2021
Janssen R&D, Spring House, PA
The JNJ AR antagonist, JNJ-63576253, is a clinical molecule for prostate cancer that is active against both wild-type androgen receptor as well as the clinically relevant AR mutant, F877L.…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.